Targeting drug resistance in tuberculosis
Dual Targeting of Mtb Resistance Mechanisms
This study is looking for new ways to help people with drug-resistant tuberculosis (TB) by using special compounds that can fight the bacteria and boost the body's immune system, so we can find better treatments for those who need them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Seattle Children's Hospital NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10899471 on NIH RePORTER |
What this research studies
This research focuses on developing new strategies to combat tuberculosis (TB) by targeting the mechanisms that allow the bacteria, Mycobacterium tuberculosis (Mtb), to resist treatment. The approach involves using drug-like compounds that can affect both replicating and non-replicating forms of the bacteria, as well as exploring host-directed therapies that enhance the body's immune response against TB. By understanding how these therapies can reduce bacterial load, the research aims to provide more effective treatment options for patients with drug-resistant TB.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with tuberculosis, especially those who have strains resistant to standard antibiotic treatments.
Not a fit: Patients who do not have tuberculosis or those with non-infectious conditions will not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for tuberculosis, particularly for patients with drug-resistant strains.
How similar studies have performed: Previous research has shown promise in targeting drug resistance mechanisms in tuberculosis, indicating that this approach could lead to significant advancements in treatment.
Where this research is happening
Seattle, United States
- Seattle Children's Hospital — Seattle, United States (Active)
Researchers
- Principal investigator: Grundner, Christoph — Seattle Children's Hospital
- Study coordinator: Grundner, Christoph
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.